We had a technical breakdown on Tuesday, an energetic recovery on Wednesday and now things are breaking down again.
Several firms hiked price targets on Portola into the $70s this week.
Because much of the Trump and Republican party agenda is predicated on healthcare reform, nothing can get done until that happens -- or they change course.
Several firms hiked price targets on Portola into the $70s this week.
This biotech has done well so far this year, but now it's time to lock in some gains.
It would be better from a trading standpoint for this market to sell off with some vigor.
Buy a shallow dip and price strength.
MRK has shaped up on the charts.
There are reasons to believe rallies in BioDelivery Sciences and Flexion Therapeutics should continue.
The answer is to really make the Exchanges the focal point of liquidity for healthcare insurance.

Columnist Conversations

Foot Locker's (FL) less than expected quarterly earnings set off a round of selling the entire athletic appare...
View Chart »  View in New Window » Gold has met the first upside target off the last setup zon...
View Chart »  View in New Window »
View Chart »  View in New Window »


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.